The Dual-Mode Transition of Myofibroblasts Derived from Hepatic Stellate Cells in Liver Fibrosis.
activation model
hepatic stellate cells
liver fibrosis
transforming growth factor β
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Oct 2023
23 Oct 2023
Historique:
received:
22
09
2023
revised:
19
10
2023
accepted:
19
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Hepatic stellate cells (HSCs) are the key promoters of liver fibrosis. In response to liver-fibrosis-inducing factors, HSCs express alpha smooth muscle actin (α-SMA) and obtain myofibroblast phenotype. Collagen secretion and high expression of α-SMA with related high cell tension and migration limitation are the main characteristics of myofibroblasts. How these two characteristics define the role of myofibroblasts in the initiation and progression of liver fibrosis is worth exploring. From this perspective, we explored the correlation between α-SMA expression and collagen secretion in myofibroblasts and the characteristics of collagen deposition in liver fibrosis. Based on a reasonable hypothesis and experimental verification, we believe that the myofibroblast with the α-SMA
Identifiants
pubmed: 37895138
pii: ijms242015460
doi: 10.3390/ijms242015460
pmc: PMC10607848
pii:
doi:
Substances chimiques
Collagen
9007-34-5
Transforming Growth Factor beta
0
Actins
0
Transforming Growth Factor beta1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 82060119
Références
Front Physiol. 2015 Dec 02;6:359
pubmed: 26696895
Nat Commun. 2013;4:2823
pubmed: 24264436
FASEB J. 2015 Mar;29(3):1043-55
pubmed: 25466902
Signal Transduct Target Ther. 2023 Jun 16;8(1):229
pubmed: 37321990
FASEB J. 2019 Nov;33(11):12435-12446
pubmed: 31419161
J Cell Biol. 1996 Jul;134(1):67-80
pubmed: 8698823
J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:173-9
pubmed: 21199529
Adv Drug Deliv Rev. 2017 Nov 1;121:27-42
pubmed: 28506744
J Clin Invest. 2014 Jul;124(7):2921-34
pubmed: 24937432
J Invest Dermatol. 2007 Mar;127(3):526-37
pubmed: 17299435
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cells. 2020 Apr 03;9(4):
pubmed: 32260126
Physiol Rev. 2008 Jan;88(1):125-72
pubmed: 18195085
Gastroenterology. 1998 Apr;114(4):842-5
pubmed: 9547102
Free Radic Biol Med. 2021 Nov 20;176:246-256
pubmed: 34614448
Nature. 2019 Nov;575(7783):512-518
pubmed: 31597160
Front Cell Dev Biol. 2022 Jul 22;10:930373
pubmed: 35938166
Nat Rev Immunol. 2022 Jan;22(1):19-32
pubmed: 34002067
J Mol Cell Cardiol. 2010 Sep;49(3):499-507
pubmed: 20488188
Lab Invest. 2012 Jan;92(1):135-50
pubmed: 21946857
Hepatology. 2023 Apr 1;77(4):1088-1089
pubmed: 36626636
Hepatology. 2014 Jan;59(1):154-69
pubmed: 23832448
Front Pharmacol. 2020 Dec 17;11:591393
pubmed: 33390969
WIREs Mech Dis. 2021 Jan;13(1):e1499
pubmed: 32713091
Nat Med. 2013 Dec;19(12):1617-24
pubmed: 24216753
Int Immunopharmacol. 2023 Jan;114:109527
pubmed: 36700762
Front Pharmacol. 2022 Feb 11;13:787748
pubmed: 35222022
Biochem Biophys Res Commun. 2012 Apr 20;420(4):743-9
pubmed: 22465012
World J Gastroenterol. 2009 Mar 28;15(12):1431-42
pubmed: 19322915
J Biomech. 2010 Jan 5;43(1):146-55
pubmed: 19800625